3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Lymphoma, Non-Hodgkin
16
Myelodysplastic Syndromes
15
Leukemia, Myeloid, Acute
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Hodgkin Disease
15
Lymphoma, Mantle-Cell
14
Multiple Myeloma
13
Waldenstrom Macroglobulinemia
12
Graft vs Host Disease
12
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma
11
Leukemia
11
Lymphoma, Follicular
10
Lymphoma, B-Cell, Marginal Zone
10
Sarcoma
9
Myeloproliferative Disorders
9
Burkitt Lymphoma
9
Tuberous Sclerosis
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Primary Myelofibrosis
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms
6
Lymphoma, Large-Cell, Immunoblastic
6
Leukemia, Myelomonocytic, Chronic
6
Congenital Abnormalities
6
Breast Neoplasms
6
Myelodysplastic-Myeloproliferative Diseases
5
Lymphoma, Large-Cell, Anaplastic
5
Lymphangioleiomyomatosis
5
Interventions
cemiplimab
2
Sirolimus
1
Prednisone
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Cutaneous Squamous Cell Carcinoma
×
Sirolimus
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts